Dermatophytic Onychomycosis Market

Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.

Dermatophytic Onychomycosis Market contains market size and forecasts of Dermatophytic Onychomycosis in Global, including the following market information:

• Global Dermatophytic Onychomycosis Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Dermatophytic Onychomycosis market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oral Medicine Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Dermatophytic Onychomycosis include Johnson & Johnson, GSK, Novartis, Pfizer, Bausch Health, Kaken Pharmaceutical, Galderma, Sanofi and Allergan, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Dermatophytic Onychomycosis companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Dermatophytic Onychomycosis Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Dermatophytic Onychomycosis Market Segment Percentages, by Type, 2021 (%)

• Oral Medicine
• External Medicine

Global Dermatophytic Onychomycosis Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Dermatophytic Onychomycosis Market Segment Percentages, by Application, 2021 (%)

• Age Under 18
• Age 18-50
• Age Above 50

Global Dermatophytic Onychomycosis Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Dermatophytic Onychomycosis Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Dermatophytic Onychomycosis revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Dermatophytic Onychomycosis revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Johnson & Johnson
• GSK
• Novartis
• Pfizer
• Bausch Health
• Kaken Pharmaceutical
• Galderma
• Sanofi
• Allergan
• Merz Pharma
• Xiuzheng Pharmaceutical
• Letai
• Qilu Pharmaceutical